A Phase 1b, Open-Label, Dose Escalation and Expansion Study of Demcizumab Plus Pembrolizumab and Demcizumab plus Pembrolizumab, Pemetrexed and Carboplatin in Patients with Locally Advanced or Metastatic Solid Tumors
|OncoMed Pharmaceuticals, Inc.
|Male and Female Patients
|U.S. Govt. ID:
|Catherine Shu: 646-317-3141 / email@example.com
The purpose of this study is to test the efficacy and safety of an experimental drug, demcizumab, when given in combination with pembrolizumab (Arm A of the study). Demcizumab is a humanized monoclonal antibody and was developed to target cancer stem cells. Demcizumab may block the growth of cancer stem cells, in addition to the remaining cancer cells, and it may also prevent the growth of new blood vessels that tumors need to grow and spread. Demcizumab, used in this study, is experimental.
This study is closed
Catherine Shu, MD
|Have you been diagnosed with advanced solid tumors?